Alumis (ALMS) Other Non-Current Assets (2023 - 2026)
Alumis (ALMS) posted quarterly Other Non-Current Assets of $1.3 million for Q4 2025, up 18485.71% year-over-year from N/an in Q4 2024, and down 5.17% quarter-over-quarter from $1.4 million in Q3 2025.
Analysis
Alumis (ALMS) Other Non-Current Assets (2023 - 2026) Analysis & Trends
Alumis (ALMS) has reported Other Non-Current Assets for 3 consecutive years, with $1.3 million the latest figure, recorded in Q4 2025.
- In Q4 2025, Other Non-Current Assets rose 18485.71% year-over-year to $1.3 million; the TTM figure through Dec 2025 stood at $1.3 million (up 18485.71% YoY), while the FY2025 annual figure was $1.3 million, up 18485.71% from the prior year.
- Other Non-Current Assets declined to $1.3 million in Q4 2025 per ALMS's latest filing, from $1.4 million in the prior quarter.
- Across five years, Other Non-Current Assets topped out at $2.5 million in Q2 2025 and bottomed at $7000.0 in Q4 2024.
- Historically, Other Non-Current Assets has averaged $1.0 million across 3 years, with a median of $1.0 million in 2023.
- Annual changes were most pronounced in 2024 — Other Non-Current Assets plunged 99.32% — and 2025, when it soared 18485.71%.
- Alumis' Other Non-Current Assets stood at $1.0 million in 2023, then slumped by 99.32% to $7000.0 in 2024, then jumped by 18485.71% to $1.3 million in 2025.
- Business Quant data shows ALMS's Other Non-Current Assets at $1.3 million in Q4 2025, $1.4 million in Q3 2025, and $2.5 million in Q2 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Other Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.51 Bn | 130.66 Bn | 2.84 Bn | 1.25 Bn |
| 2 | Regeneron Pharmaceuticals | 85.24 Bn | 77.25 Bn | 3.93 Bn | 2.31 Bn |
| 3 | Argenx Se | 63.46 Bn | 58.28 Bn | 1.37 Bn | 124.00 Mn |
| 4 | Moderna | 57.89 Bn | 52.75 Bn | 52.00 Mn | 618.00 Mn |
| 5 | Revolution Medicines | 44.02 Bn | 44.02 Bn | - | 42.45 Mn |
| 6 | BeOne Medicines | 39.95 Bn | 34.85 Bn | 1.53 Bn | 109.58 Mn |
| 7 | Alnylam Pharmaceuticals | 35.49 Bn | 32.19 Bn | 992.69 Mn | 65.13 Mn |
| 8 | Royalty Pharma | 28.43 Bn | 27.59 Bn | - | 62.96 Mn |
| 9 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 104.44 Mn |
| 10 | Alumis | 1.41 Bn | 907.50 Mn | - | 1.89 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 1.89 Mn |
| Dec 31, 2025 | 6.29 Mn |
| Sep 30, 2025 | 5.82 Mn |
| Jun 30, 2025 | 1.38 Mn |
| Mar 31, 2025 | 1.16 Mn |
| Dec 31, 2024 | 1.11 Mn |
| Sep 30, 2024 | 1.02 Mn |
| Jun 30, 2024 | 1.02 Mn |
| Mar 31, 2024 | 1.02 Mn |
| Dec 31, 2023 | 1.02 Mn |
| Sep 30, 2023 | 1.02 Mn |
| Jun 30, 2023 | 1.14 Mn |